By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


EPIRUS Biopharmaceuticals 

699 Boylston Street
11th Floor
Boston  Massachusetts   02116  U.S.A.
Phone: n/a Fax: n/a


Company News
EPIRUS Biopharmaceuticals To Present At Wedbush Life Sciences Management Access Conference 8/8/2014 9:18:35 AM
Mark H.N. Corrigan, M.D., Julie H. McHugh, And William Hunter, M.D. To Serve On EPIRUS Biopharmaceuticals Board Of Directors 7/15/2014 11:25:47 AM
EPIRUS Biopharmaceuticals And Zalicus Inc. (ZLCS) Complete Merger - Combined Company Will Trade As EPIRUS Biopharmaceuticals 7/15/2014 10:46:32 AM
Zalicus Inc. (ZLCS) And EPIRUS Biopharmaceuticals Agree Zalicus Stockholders To Own 19 Percent Of Combined Company Post-Merger 6/25/2014 8:59:00 AM
Boston-Based EPIRUS Biopharmaceuticals Reels In $36 Million Series B, Will Merge With Zalicus Inc. (ZLCS) In All-Stock Deal 4/16/2014 6:31:56 AM
EPIRUS Biopharmaceuticals And Ranbaxy Laboratories (RANBAXY.BO) Announce Signing Of BOW015 Licensing Partnership For Broad Range Of Territories 1/8/2014 9:08:39 AM
EPIRUS Biopharmaceuticals and Orygen Biotecnologia Announce Signing of Multiproduct Biosimilar Development, Manufacturing and Commercialization Collaboration for Brazil 10/22/2013 7:11:19 AM
EPIRUS Biopharmaceuticals Touts Positive Phase 3 Data for Remicade Biosimilar 8/29/2013 7:10:31 AM